Background: Atherosclerosis is an inflammatory disease. Many studies demonstrated that hyperglycemia is not only increased inflammatory response, but also is a cause of atherosclerosis, implying that glucose metabolic status may be an important stratification factor when analyzing the relationship between inflammatory levels and subclinical carotid atherosclerosis. The aim of the present study is to assess the relationship between inflammatory levels and subclinical carotid atherosclerosis, stratified by different glucose metabolic status in a general population.
representing 31% of all global deaths, 1 and it has reached epidemic proportions (about 40% of all deaths) of in China. 2 The growing burden of CVDs demonstrates an immediate need to clarify the underlying disease mechanisms. This improved understanding will enhance disease prevention. Many evidences demonstrated that atherosclerosis is the main pathological basis of CVDs. 3, 4 Atherosclerosis is an inflammatory disease. 5 At the same time, many studies have shown that hyperglycemia may itself accelerate atherosclerosis. Hyperglycemia induces glycosylated proteins that interact with a specific receptor (a member of the immunoglobulin superfamily of receptors) present on all cells relevant to the atherosclerotic process. These cells include monocyte-derived macrophages, endothelial cells, and smooth muscle cells. 6, 7 It has also been proposed that hyperglycemia accelerates inflammatory processes through the formation of advanced glycosylation end products (AGEs). 8 These studies suggest that glucose metabolic status may be an important stratification factor when analyzing the relationship between inflammatory levels and subclinical carotid atherosclerosis. Detectable but still relatively low levels of high-sensitivity C-reactive protein (hs-CRP), which is known to reflect chronic low-grade inflammation, has been found to be associated with atherosclerosis and CVDs. [9] [10] [11] Many publications have demonstrated that, in addition to its association with subclinical carotid atherosclerosis (as defined by increased carotid intima-media thickness [IMT] and plaques), 12, 13 hs-CRP also has a strong association with type 2 diabetes mellitus (T2DM). 14 Thus , it is conceivable that glucose metabolic status may be a crucial stratification factor for the relationship between subclinical carotid atherosclerosis and hs-CRP. However, to date, few studies have assessed the relationship between subclinical carotid atherosclerosis and hs-CRP stratified by glucose metabolic status. Hence, the aim of our study was to investigate how hs-CRP relates to subclinical carotid atherosclerosis among members of the general adult population with different glucose metabolic statuses.
| METHODS

| Study population
The study sample of this cross-sectional study was taken from participants in the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) Cohort, details of which have been published elsewhere. 15 This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The protocols and procedures of the study were approved by the Institutional Review Board of Tianjin Medical University, and written informed consent was obtained from each participant.
A total of 8949 subjects participated in this study. Some subjects were excluded because of incomplete laboratory data (n = 1) or a history of CVDs (n = 742) or cancer (n = 161) or lack the data of plaque area (n = 70). After excluding those subjects, the final cross-sectional analysis population comprised 7975 participants including 5988 subjects with normal blood glucose metabolic status, 1434 subjects with prediabetes and 553 subjects with T2DM.
| Assessment of glucose metabolic status
Fasting blood glucose (FBG) and HbA1c were measured by standard methods. 15 To measure 2-hour serum glucose, subjects were given a standard 75-g glucose solution, and serum glucose was measured at 2 hours after administration during the oral glucose tolerance test.
Diabetes can be classified into four clinical categories: type 1 diabetes, type 2 diabetes, other specific types of diabetes because of other causes and gestational diabetes mellitus. 16 In undiagnosed participants, T2DM was defined as an FBG ≥126 mg/dL (7.0 mmol/L), or oral glucose tolerance test (OGTT) ≥200 mg/dL (11.1 mmol/L), or HbA1c ≥48 mmol/mol (6.5%) or a history of T2DM based on the American Diabetes Association 2014 criteria. 16 Prediabetes was defined as having impaired fasting glucose levels [IFG; 110-126 mg/ dL (6.1-7.0 mmol/L)] or impaired glucose tolerance [IGT; 2-hour values during OGTT of 140-200 mg/dL (7.8-11.1 mmol/L)]. 17 In the subjects with normal glucose metabolic status, exclusion criteria were diabetes and prediabetes.
| Assessment of hs-CRP
Levels of serum hs-CRP were measured by high-sensitivity immunoturbidimetric assay using a Hitachi 917 analyzer (Roche Diagnostics, Mannheim, Germany), and expressed as mg/L. The detection limit for hs-CRP was 0.01 mg/L. To investigate how the hs-CRP levels were related to the prevalence and incidence of increased IMT or plaques, we divided participants into four categories according to observed concentrations of hs-CRP. IMT was evaluated as the distance between the lumen-intima interface and the media-adventitia interface. Intima and media thicknesses were measured as the distance from the main edge of the first to the main edge of the second echogenic line. Increased IMT was characterized by the largest IMT (≥1.0 mm) in the CCA on the left or right sides and the largest IMT (≥1.2 mm) in the carotid sinus on the left or right sides. 18 The procedure for detecting plaques involved scanning the near and far walls of the common carotid arteries, the carotid bifurcation, the external carotid artery, and the internal carotid artery. We defined a plaque as a thickness of ≥1.5 mm as measured from the media-adventitia interface to the intima-lumen interface. The area of each plaque was calculated as the lesion height (in mm) multiplied by the lesion length (in mm). In those participants with multiple plaques, plaque area was the sum of the areas of all plaques observed.
| Assessment of IMT, plaques, and plaque area
| Assessment of other variables
Blood pressure (BP) was measured twice from the right arm using an automatic device (Andon, Tianjin, China) after 5 minutes of rest in a seated position. The mean of these two measurements was taken as the BP value. Triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured using by standard methods. 15 Fibrinogen was measured according to Clauss using STA Fibrinogen 
| Statistical analysis
All statistical analyses were performed using the Statistical Analysis 
| RESULTS
In the cross-sectional analysis, 5988 of the 7975 participants (75.1%) were at normal glucose metabolic status, 1434 of the 7975 participants (18.0%) were prediabetes, 553 of the 7975 participants (6.93%) were T2DM. Overall mean AE SD age was 52.1 AE 10.5 years. The overall prevalence of increased IMT and plaques were 27.3% (2180 of 7975) and 21.3% (1700 of 7975), respectively. The characteristics of participants across blood glucose metabolic status for cross-sectional analysis are presented in Table 1 . Compared to participants free of diabetes, those with prediabetes or T2DM tended to be older, to have higher proportion of males, to have higher BMI, WC, and levels of TC, FBG, LDL-C, fibrinogen, and hs-CRP, to have bigger plaque area, and to have a higher SBP, DBP, but a lower level of HDL-C (all P=value < 0.0001); in addition, a higher proportion of these participants were current smokers and drinkers and had a family history of diabetes; however, a lower proportion of these participants had a family history of CVDs and hypertension (P-value < 0.05). Other than these results, no significant differences were observed between the participants with different blood glucose metabolic statuses.
In this analysis, we divided hs-CRP levels into four categories according to observed concentrations of hs-CRP of participants with different blood glucose metabolic statuses. Table 2 shows the crude and adjusted relationship between quartiles of hs-CRP and IMT in participants with different blood glucose metabolic statuses. After adjusting for potential confounders, in the final multivariate models, the ORs (95% CI) for IMT across hs-CRP quartiles were as follows: 1.00 (reference), 1.10 (0.88-1.38), 1.08 (0.86-1.35), and 1.32 (1.06-1.66) in blood glucose-normal subjects (P for trend = 0.011); 1.00 (reference), 1.33 (0.92-1.91), 1.33 (0.93-1.91) and 1.59 (1.10-2.30) in prediabetic subjects (P for trend = 0.04); 1.00 (reference), 0.94 (0.54-1.62), 1.17 (0.65-2.12) and 0.98 (0.55-1.76) in T2DM subjects (P for trend = 0.97), respectively. Table 3 shows the crude and adjusted relationship between quartiles of hs-CRP and plaques in participants with different blood glucose metabolic statuses. After adjusting for potential confounders, in the final multivariate models, the ORs (95% CI) for plaques across hs-CRP quartiles were as follows: 1.00 (reference), 1.21 (0.96-1.52), 1.31 (1.05-1.64), and 1.39 (1.11-1.75) in blood glucosenormal subjects (P for trend = 0.014); 1.00 (reference), 1.03 (0.70-1.50), 1.32 (0.92-1.91) and 1.76 (1.21-2.56) in prediabetic subjects (P for trend <0.001); 1.00 (reference), 0.96 (0.57-1.63), 0.78 (0.44-1.37) and 1.47 (0.85-2.57) in T2DM subjects (P for trend = 0.09), respectively. The adjusted relationships between quartiles of hs-CRP and plaque area were shown in Table 3 . The plaque area in the lowest and the second lowest quartiles was significantly different from the plaque area in the highest quartile of serum hs-CRP concentration (Bonferroni-corrected P-value < 0.05) in blood glucose-normal and prediabetic subjects. Similar results were not observed in T2DM subjects.
| DISCUSSION
The present study first evaluated the relationship between hs-CRP and subclinical carotid atherosclerosis stratified by the different glucose metabolic status in a general population. The results showed that the relationship between hs-CRP and subclinical carotid atherosclerosis was stronger in adults with prediabetes than with normal glucose metabolic status, but similar results were not observed in patients with T2DM.
Because age, sex, and BMI have been shown to be related to hs-CRP levels and to subclinical carotid atherosclerosis, 20, 21 we first adjusted for these variables in model 1. Adjustment for these variables only slightly attenuated the relationship we observed between hs-CRP and subclinical carotid atherosclerosis. This indicates that the effects of these variables on the relationship are weak. Next, we [22] [23] [24] as well as for genetic factors. 25 These genetic factors include family history of CVDs, hypertension, and diabetes, all of which have been shown to have an association with CVDs. 26, 27 The results of model 2, in which we adjusted for all variables, did not change significantly compared with model 1.
The hypothesis of this study is that glucose metabolic status maybe a crucial stratification factor for the relationship between hs-CRP and subclinical carotid atherosclerosis. So far, there have been conflicting findings regarding the relationship between hs-CRP and subclinical carotid atherosclerosis in diabetic patients. Three crosssectional studies and a cohort study reported that hs-CRP was related to IMT in patients with diabetes. [28] [29] [30] [31] In contrast, a cross-sectional study showed that CRP was not correlated of carotid artery IMT in men with diabetes. 32 On the other hand, to date, two cross-sectional studies found that hs-CRP levels were significantly correlated with the IMT of nondiabetic patients, 28, 29 but a cohort study reported that hs-CRP was no longer independently associated with IMT progression in the nondiabetic subjects. 30 Because prediabetes is an important precursor of T2DM, our research analyzed the relationship between hs-CRP and subclinical carotid atherosclerosis in participants with T2DM, prediabetes, and normal glucose metabolic status. However, contrary to a previous study, 30 our study found that hs-CRP was related to subclinical carotid atherosclerosis in both prediabetic patients and individuals with normal glucose metabolic status.
Although the reasons for these discrepancies remain unclear, the differences in confounding factors, study design, stratified method, ethnic differences might partly explain the cause for conflicting results.
Further studies are necessary to explore whether these results of the present study can also be observed in other general populations.
The present observation of differences between adults with normal glucose metabolic status and T2DM regarding hs-CRP and subclinical carotid atherosclerosis may be explained. First, one possible cofounder in our study may result from the fact that T2DM patients are more likely to be using glucose-lowering therapies, such as metformin, pioglitazone, and empagliflozin. 33 Furthermore, one study has demonstrated that, in addition to lowering blood glucose levels, those therapies also play an important role in atherosclerosis. 33 Meanwhile, it is known that T2DM is accompanied by some complications, including nephropathy, neuropathy, cardiomyopathy, and so on. 34 Another possible confounding effect might have been an obviously larger proportion of patients with complication-treatment, for example, statins in the T2DM group, which known to affect inflammation, but this was not observed. Second, it has also indicated that our understanding of pathogenesis of CVDs because of diabetes has improved significantly, with hyperinsulinemia, insulin resistance, and hypercoagulability playing a role in the excess CVDs-risk in patients with diabetes. 35, 36 Those Some potential mechanisms by which hs-CRP may play a role in atherosclerosis in general population have been implicated. First, hs-CRP deposition induces recruitment of monocytes to the atherosclerotic lesion. Monocyte infiltration into the arterial wall is a two-step process that involves adherence to the activated endothelium and directed migration to a chemotactic gradient. 37 Second, hs-CRP upregulates angiotensin type 1 receptor (AT 1 -R) -mediated atherosclerotic events in vascular smooth muscle in vitro and in vivo. 38 Third, hs-CRP may also promote atherogenesis by inducing endothelial dysfunction. 39, 40 Furthermore, in this study, we found that the relationship between hs-CRP and subclinical carotid atherosclerosis was more marked in subjects with prediabetes than with normal blood glucose metabolic status. Some findings suggested that hyperglycemia not only facilitates inflammatory processes, 8 study because of lack of information. Finally, our results cannot exclude that hs-CRP is associated with atherosclerosis in diabetic patients as this subgroup of patients probably already has an elevated hs-CRP. Therefore, further cohort studies are needed to verify whether baseline hs-CRP values can predict the progress of carotid atherosclerosis in diabetic patients.
| CONCLUSIONS
The present study suggests that elevated hs-CRP levels are more strongly related to the subclinical carotid atherosclerosis in adults with prediabetes than with normal glucose metabolic status. But this relationship has disappeared in patients with T2DM. These results imply that inflammatory levels may contribute to the regulation of subclinical carotid atherosclerosis by the different glucose metabolic status.
Further cohort study and clinical trial are needed to verify our results and find more effective strategy to prevent subclinical carotid atherosclerosis by controlling inflammation levels.
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